WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530122
CAS#: 299460-62-1
Description: UCB-35440 is a 5-lipoxygenase inhibitor and a histamine H1 receptor antagonist potentially for the treatment of dermatitis.
Hodoodo Cat#: H530122
Name: UCB-35440
CAS#: 299460-62-1
Chemical Formula: C31H34ClN5O4
Exact Mass: 575.23
Molecular Weight: 576.090
Elemental Analysis: C, 64.63; H, 5.95; Cl, 6.15; N, 12.16; O, 11.11
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: UCB-35440, UCB35440, UCB 35440
IUPAC/Chemical Name: 5-(4-(Carbamoyl(hydroxy)amino)but-1-ynyl)-2-(2-(4-((R)-(4-chlorophenyl)-phenyl-methyl)piperazin-1-yl)ethoxy)benzamide
InChi Key: KHVLZYHEWIBDOU-GDLZYMKVSA-N
InChi Code: InChI=1S/C31H34ClN5O4/c32-26-12-10-25(11-13-26)29(24-7-2-1-3-8-24)36-18-16-35(17-19-36)20-21-41-28-14-9-23(22-27(28)30(33)38)6-4-5-15-37(40)31(34)39/h1-3,7-14,22,29,40H,5,15-21H2,(H2,33,38)(H2,34,39)/t29-/m1/s1
SMILES Code: O=C(N)C1=CC(C#CCCN(C(N)=O)O)=CC=C1OCCN2CCN([C@@H](C3=CC=C(Cl)C=C3)C4=CC=CC=C4)CC2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 576.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le Lamer S, Amighi K. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm. 2006 Nov;64(3):360-8. PubMed PMID: 16846725.
2: Giannaras A, Selig W, Ellis J, Hullinger T. The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur J Pharmacol. 2005 Jan 4;506(3):265-71. PubMed PMID: 15627437.
